ANTICANCER RESEARCH International Journal of Cancer Research and Treatment

ISSN: 0250-7005

Volume 37, Number 1, January 2017

Contents Reviews Clinical Implications of High-mobility Group Box-1 (HMGB1) and the Receptor for Advanced Glycation End-products (RAGE) in Cutaneous Malignancy: A Systematic Review. A.H. NGUYEN, S.Q. DETTY, D.K. AGRAWAL (Omaha, NE, USA) ...... 1

Parenchymal-sparing Hepatectomy as the New Doctrine in the Treatment of Liver-metastatic Colorectal Disease: Beyond Oncological Outcomes. D. MORIS, D. DIMITROULIS, S. VERNADAKIS, A. PAPALAMPROS, E. SPARTALIS, A. PETROU, T.M. PAWLIK, E. FELEKOURAS (Cleveland; Columbus, OH, USA; Athens, Greece) ...... 9

Three Pathways of Colonic in Rats. C.A. RUBIO (Stockholm, Sweden) ...... 15

Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme. J. POLIVKA JR, J. POLIVKA, L. HOLUBEC, T. KUBIKOVA, V. PRIBAN, O. HES, K. PIVOVARCIKOVA, I. TRESKOVA (Plzen, Czech Republic) ...... 21

Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer. C. DAMASKOS, S. VALSAMI, M. KONTOS, E. SPARTALIS, T. KALAMPOKAS, E. KALAMPOKAS, A. ATHANASIOU, D. MORIS, A. DASKALOPOULOU, S. DAVAKIS, G. TSOUROUFLIS, K. KONTZOGLOU, D. PERREA, N. NIKITEAS, D. DIMITROULIS (Athens, Greece; Aberdeen, UK; Cleveland, OH, USA) ...... 35 Experimental Studies KIF11 Is Required for Spheroid Formation by Oesophageal and Colorectal Cancer Cells. T. IMAI, N. OUE, K. SENTANI, N. SAKAMOTO, N. URAOKA, H. EGI, T. HINOI, H. OHDAN, K. YOSHIDA, W. YASUI (Hiroshima; Gifu; Kure, Japan) ...... 47 Contents continued on the back cover ISSN (print): 0250-7005 ISSN (online): 1791-7530 Editorial Board Editorial Office: International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki 19014, P. A. ABRAHAMSSON , Malm , Sweden Pat M. KUMAR, Manchester, UK ö Greece. Tel / Fax: +30-22950-53389. B. B. AGGARWAL, Houston, TX, USA Shant KUMAR, Manchester, UK U.S. Branch: Anticancer Research USA, Inc., 111 Bay Avenue, T. AKIMOTO, Kashiwa, Chiba, Japan O. D. LAERUM, Bergen, Norway Highlands, NJ 07732, USA. P. Z. ANASTASIADIS, Jacksonville, FL, USA F. J. LEJEUNE, Lausanne, Switzerland E-mails: Editorial Office: [email protected] A. ARGIRIS, San Antonio, TX, USA S. LINDER, Link ping, Sweden Managing Editor: [email protected] ö J. P. ARMAND, Toulouse, France L. F. LIU, Piscataway, NJ, USA ANTICANCER RESEARCH supports: (a) the establishment and the V. I. AVRAMIS, Los Angeles, CA, USA D. M. LOPEZ, Miami, FL, USA activities of the INTERNATIONAL INSTITUTE OF ANTICANCER D.-T. BAU, Taichung, Taiwan, ROC E. LUNDGREN, Um ea, Sweden RESEARCH (IIAR; Kapandriti, Attiki, Greece); and (b) the organization ° of the International Conferences of Anticancer Research. The IIAR is a G. BAUER, Freiburg, Germany Y. MAEHARA, Fukuoka, Japan member of UICC. For more information about ANTICANCER E. E. BAULIEU, Le Kremlin-Bicetre, France J. MAHER , London, UK RESEARCH, IIAR and the Conferences, please visit the IIAR website: E. J. BENZ , Jr., Boston, MA, USA J. MARESCAUX, Strasbourg, France www.iiar-anticancer.org J. BERGH, Stockholm, Sweden J. MARK, Sk vde, Sweden ö Publication Data: ANTICANCER RESEARCH (AR) is published F. T. BOSMAN, Lausanne, Switzerland S. S. MARTIN, Baltimore, MD, USA bimonthly from January 1981 to December 2008 and monthly from M. BOUVET, La Jolla, CA, USA S. MITRA, Houston, TX, USA January 2009. Each annual volume comprises 12 issues. Annual Author J. BOYD, Miami, FL, USA S. MIYAMOTO, Fukuoka, Japan and Subject Indices are included in the last issue of each volume. ANTICANCER RESEARCH Vol. 24 (2004) and onwards appears online G. BROICH, Monza, Italy S. MONCADA, Manchester, UK with Stanford University HighWire Press from April 2009. . S. BRULAND, Oslo, Norway M. MUELLER, Villingen-Schwenningen, Ø Copyright: On publication of a manuscript in AR, which is a J. M. BUATTI, Iowa City, IA, USA Germany copyrighted publication, the legal ownership of all published parts of M. M. BURGER, Basel, Switzerland F. M. MUGGIA, New York, NY, USA the paper passes from the Author(s) to the Journal. M. CARBONE, Honolulu, HI, USA M. NAMIKI, Kanazawa, Ishikawa, Japan Annual Subscription Rates 2017 per volume: Institutional subscription C. CARLBERG, Kuopio, Finland R. NARAYANAN, Boca Raton, FL, USA US$ 1,898.00 (online) or US$ 2,277.00 (print & online). Personal J. CARLSSON, Uppsala, Sweden K. NILSSON, Uppsala, Sweden subscription US$ 897.00 (online) or US$ 1,277.00 (print & online). A. F. CHAMBERS, London, ON, Canada S. PATHAK, Houston, TX, USA Prices include rapid delivery and insurance. The complete previous volumes of Anticancer Research (Vol. 1-36, 1981-2016) are available at P. CHANDRA, Frankfurt am Main, Germany J.L. PERSSON, Malm , Sweden ö 50% discount on the above rates. Portsmouth, UK L. CHENG, Indianapolis, IN, USA G. J. PILKINGTON, Subscription Orders: Orders can be placed at agencies, bookstores, or J.-G. CHUNG , Taichung, Taiwan, ROC C. D. PLATSOUCAS, Norfolk, VA, USA directly with the Publisher. (e-mail: [email protected]) R. CLARKE, Washington, DC, USA A. POLLIACK, Jerusalem, Israel Advertising: All correspondence and rate requests should be E. DE CLERCQ, Leuven, Belgium M. RIGAUD, Limoges, France addressed to the Editorial Office. W. DEN OTTER, Amsterdam , The Netherlands U. RINGBORG, Stockholm, Sweden Book Reviews: Recently published books and journals should be sent to E. P. DIAMANDIS, Toronto, ON, Canada M. ROSELLI, Rome, Italy the Editorial Office. Reviews will be published within 2-4 months. G. TH. DIAMANDOPOULOS, Boston, MA, USA S.T. ROSEN, Duarte, CA, USA Articles in ANTICANCER RESEARCH are regularly indexed in all D. W. FELSHER , Stanford, CA, USA A. SCHAUER, G ttingen, Germany bibliographic services, including Current Contents (Life Sciences), Science ö Citation Index, Index Medicus, Biological Abstracts, PubMed, Chemical J. A. FERNANDEZ-POL, Chesterfield, MO, USA M. SCHNEIDER, Wuppertal, Germany Abstracts, Excerpta Medica, University of Sheffield Biomedical Information I. J. FIDLER, Houston, TX, USA J. SEHOULI, Berlin, Germany Service, Current Clinical Cancer, AIDS Abstracts, Elsevier Bibliographic A. P. FIELDS, Jacksonville, FL, USA A. SETH, Toronto, ON, Canada Database, EMBASE, Compendex, GEOBASE, EMBiology, Elsevier BIOBASE, H. FU, Atlanta, GA, USA G. V. SHERBET, Newcastle-upon-Tyne, UK FLUIDEX, World Textiles, Scopus, Progress in Palliative Care, Cambridge B. FUCHS, Zurich, Switzerland A. SLOMINSKI, Birmingham, AL, USA Scientific Abstracts, Cancergram (International Cancer Research Data D. FUCHS, Innsbruck, Austria G.-I. SOMA, Kagawa, Japan Bank), MEDLINE, Reference Update - RIS Inc., PASCAL-CNRS, Inpharma- Reactions (Datastar, BRS), CABS, Abstracts, Telegen Abstracts, G. GABBIANI, Geneva, Switzerland G. S. STEIN, Burlington, VT, USA Abstracts, Nutrition Research Newsletter, Dairy Science Abstracts, R. GANAPATHI, Charlotte, NC, USA T. STIGBRAND, Ume °a, Sweden Current Titles in Dentistry, Inpharma Weekly, BioBase, MedBase, CAB A. F. GAZDAR, Dallas, TX, USA T. M. THEOPHANIDES, Athens, Greece Abstracts/Global Health Databases, Investigational Drugs Database, VINITI J. H. GESCHWIND, Baltimore, MD, USA P. M. UELAND, Bergen, Norway Abstracts Journal, Leeds Medical Information, PubsHub, Sociedad Iberoamericana de Informaci n Cient f ca (SIIC) Data Bases. A. GIORDANO, Philadelphia, PA, USA H. VAN VLIERBERGHE, Ghent, Belgium ó í í G. GITSCH, Freiburg, Germany R. G. VILE, Rochester, MN, USA Obtaining permission to reuse or reproduce our content: AR has partnered R. H. GOLDFARB, Guilford , CT , USA M. WELLER, Zurich, Switzerland with Copyright Clearance Center (CCC) to make it easy to secure permissions to reuse its content. Please visit www.copyright.com and enter L. HELSON, Quakertown, PA, USA J. WESTERMARCK, Turku, Finland the title that you are requesting permission for in the ‘Get Permission’ R. HENRIKSSON, Ume , Sweden B. WESTERMARK, Uppsala, Sweden å search box. For assistance in placing a permission request, Copyright R. M. HOFFMAN, San Diego, CA, USA Y. YEN, Duarte, CA, USA Clearance Center can be contacted directly at: Copyright Clearance Center, S. C. JHANWAR, New York, NY, USA M.R.I. YOUNG, Charleston, SC, USA 222 Rosewood Drive, Danvers, MA 01923 USA. Phone: +1-978-750- J. V. JOHANNESSEN, Oslo, Norway B. ZUMOFF, New York, NY, USA 8400. Fax: +1-978-646-8600. E-mail: [email protected]. B. KAINA, Mainz, Germany The Editors and Publishers of ANTICANCER RESEARCH accept no P. -L. KELLOKUMPU-LEHTINEN, Tampere, responsibility for the opinions expressed by the contributors or for the G. J. DELINASIOS, Athens, Greece content of advertisements appearing therein. Finland Managing Editor and D. G. KIEBACK , Schleswig, Germany Executive Publisher Copyright© 2017, Ιnternational Institute of Anticancer Research R. KLAPDOR, Hamburg, Germany (Dr. George J. Delinasios), All rights reserved. S. D. KOTTARIDIS, Athens, Greece J. G. DELINASIOS, Athens, Greece D.T.P. BY IIAR G. R. F. KRUEGER, K ln, Germany Managing Editor (1981-2016) PRINTED BY ENTYPO, ATHENS, GREECE. PRINTED ON ACID-FREE PAPER ö ANT ICA NCER RES EA RCH International Journal of Cancer Research and Treatment ISSN (print): 0250-7005, ISSN (online): 1791-7530

VOLUME 37 2017 ANTICANCER RESEARCH 37 : (2017)

Editorial Board

P. A. Abrahamsson Department of Urology, Skåne University Hospital, Lund University, Malmö, Sweden B. B. Aggarwal Cytokine Research Laboratory, Department of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA T. Akimoto Division of Particle Therapy and Department of Radiation Oncology, National Cancer Center East, Kashiwa, Chiba, Japan P. Z. Anastasiadis Department of Cancer Biology, Mayo Cancer Center, Jacksonville, FL, USA A. Argiris Division of Hematology/Oncology, UT Health Science Center at San Antonio, San Antonio, TX, USA J. P. Armand Institut Claudius Regaud , Toulouse , France V. I. Avramis Div ision of Hematology/Oncology, Childrens Hospital, Los Angeles, CA, USA D.-T. Bau Terry Fox Cancer Research Lab, China Medical University Hospital, Taichung, Taiwan, ROC G. Bauer Abteilung Virologie, Institut f ür Medizinische Mikrobiologie und Hygiene, Universit ät Freiburg, Germany E. E. Baulieu INSERM U488 and College de France, Le Kremlin- Bic etre, France E. J. Benz, Jr. Dana-Farber Cancer Institute, Boston, MA, USA J. Bergh Department of Clinical and Molecular Medicine, Radiumhemmet, Karolinska Inst itute , Stockholm, Sweden F. T. Bosman Institute of , University of Lausanne, Switzerland M. Bouvet Department of Surgery, University of California San Diego, Moores Cancer Center, La Jolla, CA, USA J. Boyd Department of Human and Molecular Genetics, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA G. Broich Gruppo Policlinico di Monza, Monza, Italy Ø. S. Bruland Department of Medical Oncology-Radiotherapy, Norwegian Radium Hospital, Oslo, Norway J. M. Buatti Department of Radiation Oncology, University of Iowa, Iowa City, IA, USA M. M. Burger Novartis, Basel, Switzerland M. Carbone Cancer Research Center of Hawaii, Honolulu, HI, USA C. Carlberg Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland J. Carlsson Department of Biomedical Radiation Sciences, Uppsala University, Sweden A. F. Chambers Department of Oncology, London Regional Cancer Center, London, Ont ario , Canada P. Chandra Abt. für Molekularbiologie, Klinikum Wolfgang Goethe-Universität, Frankfurt am Main, Germany L. Cheng Department of Pathology, Indiana University School of Medicine, Indianapolis, IN, USA J.-G. Chung Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, ROC R. Clarke Georgetown University Medical Center, Washington, DC, USA E. De Clercq Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium W. Den Otter VUMC, Department of Urology, Amsterdam, The Netherlands E. P. Diamandis Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto , Ont ario , Canada G. Th. Diamandopoulos Department of Pathology, Harvard Medical School, Boston, MA, USA D. W. Felsher Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA J. A. Fernandez-Pol Metalloproteomics, LLC, Chesterfield, MO, USA I. J. Fidler Department of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston , TX, USA A. P. Fields Department of Cancer Biology, College of Medicine, Mayo Clinic, Jacksonville, FL, USA H. Fu Discovery and Developmental Therapeuticis Program of Winship Cancer Institute, Emory University, Atlanta, GA, USA B. Fuchs Balgrist University Hospital, Zurich, Switzerland D. Fuchs Center for Chemistry and Biomedicine, Innsbruck Medical University, Innsbruck, Austria G. Gabbiani Department of Pathology, University of Geneva, Switzerland

continued ANTICANCER RESEARCH 37 : (2017)

R. Ganapathi Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA A. F. Gazdar Hamon C enter for Therapeutic Oncology Research, University of Texas Southeastern Medical Center, Dallas, TX, USA J. H. Geschwind Interventional Radiology Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA A. Giordano Sbarro Inst itute for Cancer Research, Temple University, Philadelphia, PA, USA G. Gitsch Department of Gynecology and Obstetrics, University of Freiburg, Germany R. H. Goldfarb R. H. Goldfarb Sopherion Therapeutics, LLC and Translational Oncology and ImmunoEngineering Consulting, Guilford, CT, USA L. Helson Sign Path Pharma, Inc., Quakertown, PA, USA R. Henriksson Department of Experimental Oncology, Umeå University, Umeå, Sweden R. M. Hoffman Department of Surgery , University of California, San Diego, CA, USA S. C. Jhanwar Lab oratory of Solid Tumor Genetics, Department of Medicine, Memorial Sloan-Kettering Cancer C enter , New York, NY, USA J. V. Johannessen Department of Pathology, The Norwegian Radium Hospital, Oslo, Norway B. Kaina Institute of Toxicology, University of Mainz, Germany P. -L. Kellokumpu-Lehtinen Department of Oncology and Radiotherapy, Tampere University Hospital, Tampere, Finland Helios Medical Center Schleswig, Schleswig, Germany D. G. Kieback R. Klapdor Medical Clinic, University of Hamburg, Germany S. D. Kottaridis Department of Virology, Hellenic Anticancer Institute, Athens, Greece G. R. F. Krueger Center of Anatomy II, University of Cologne Medical School, Cologne, Germany Pat M. Kumar Department of Biological Sciences, Manchester Metropolitan University, Manchester, UK Shant Kumar Department Pathology, University of Manchester Medical School, Manchester, UK O. D. Laerum Department of Pathology, The Gade Institute, University of Bergen, Norway F. J. Lejeune Fondation du Centre Pluridisciplinaire d' Oncologie, CHUV, Lausanne, Switzerland S. Linder Department of Medicine and Health, Linköping University, Linköping, Sweden L. F. Liu Department of , UMD of New Jersey, Piscataway, NJ, USA D. M. Lopez Department of Microbiology and Immunology, University of Miami School of Medicine, Miami, FL, USA E. Lundgren Unit of Applied Cell and Molecular Biology, University of Ume a¨, Sweden Y. Maehara Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan J. Maher Department of Research Oncology, Division of Cancer Studies, King’s College London School of Medicine, Guy’s Hospital Campus, London, UK J. Marescaux IRCAD, University of Strasbourg, France J. Mark Department of Pathology, Kärnsjukhuset, Skövde, Sweden S. S. Martin Department of Physiology, University of Maryland School of Medicine, Baltimore, MD, USA S. Mitra The Methodist Hospital Research Institute (TMHRI), Houston , TX, USA S. Miyamoto Department of Obstetrics and Gynecology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan S. Moncada Manchester Cancer Research Centre, University of Manchester, Manchester, UK Hochschule Furtwangen University, Villingen-Schwenningen, Germany M. Mueller F. M. Muggia New York University Cancer Institute, School of Medicine, NY, USA M. Namiki Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa City, Ishikawa, Japan R. Narayanan Department of Biological Sciences, Florida Atlantic University, Boca Raton, FL, USA K. Nilsson Rudbeck Laboratory, Department of Genetics and Pathology, Uppsala University Hospital, Sweden S. Pathak Department of , University of Texas, Houston, TX, USA J. L. Persson Section for Experimental Cancer Research, Clinical Research Center, Lund University, Malmö, Sweden

continued ANTICANCER RESEARCH 37 : (2017)

G. J. Pilkington Department of Cellular and Molecules Neurooncology, School of Pharmacy and Biomedical Sciences, University of Portsmouth , UK C. D. Platsoucas College of Sciences, Old Dominion University, Norfolk, VA , USA A. Polliack Department of H ae matology, Hadassah University Hospital and Medical School, Jerusalem, Israel M. Rigaud Lab oratory Biochimie et Génétique Molec ules , Fac ult é de Médecine de Limoges, France U. Ringborg Department of General Oncology, Karolinska Hospital, Stockholm, Sweden M. Roselli Department of Medical Oncology, University of Rome “Tor Vergata”, Italy S.T. Rosen Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA, USA A. Schauer Zentrum Pathologie, Georg-August Universität, Göttingen, Germany M. Schneider Department of Organic Chemistry, Bergische University, Wuppertal, Germany J. Sehouli Department of Gynecology, Center for Oncological Surgery, Charité Comprehensive Cancer Center, Berlin, Germany A. Seth Lab oratory of Molec ular Pathology, Sunnybrook Research Institute and University of Toronto, Ont ario , Canada G. V. Sherbet Cancer Research Unit, University of Newcastle -upon -Tyne, UK A. Slominski Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL, USA Department of Integrated and Holistic Immunology, Faculty of Medicine, Kagawa University, G.-I. Soma Kagawa, Japan

G. S. Stein Department of Biochemistry, College of Medicine, University of Vermont, Burlington, VT, USA T. Stigbrand Department of Immunology, Ume a¨ University, Ume a¨, Sweden T. M. Theophanides Department of Chemistry, Technical University of Athens, Greece P. M. Ueland Clinical Pharmacolocy Unit, Department of Pharmacology, University of Bergen, Norway H. Van Vlierberghe Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent, Belgium R.G. Vile Department of Immunology, Mayo Clinic, Rochester, MN, USA M. Weller Department of Neurology, University Hospital Zurich, Zurich, Switzerland J. Westermarck Centre for Biotechnology, University of Turku, Turku, Finland B. Westermark Rudbecklaboratoriet, Department of Genetics and Pathology, University of Uppsala, Sweden Y. Yen Department of Molecular Pharmacology, City of Hope, Duarte, CA, USA M. R. I. Young Ralph H. Johnson VA Medical Center, Medical University of South Carolina, Charleston, SC, USA B. Zumoff Div ision of Endocrinology and Metabolism, Beth Israel Medical Center, New York, NY, USA ANTICANCER RESEARCH 37 : (2017)

Acknowledgements

The IIAR appreciates the support of the following Foundations, Institutions, Organizations and Universities for the works published in Anticancer Research, Volume 36, 2016.

A.P. Moeller Foundation, Copenhagen, Denmark Bio and Medical Technology Department Program, Academic Scholarship, Seoul National University College National Research Foundation (NRF), Ministry of of Medicine Alumni Association, Port Washington, NY, Education, Science and Technology, Seoul, Republic of U.S.A. Korea Academy of Finland, Helsinki, Finland Biobanking and BioMolecular resources Research Advanced Research Foundation Inc., New Rochelle, NY, Infrastructure (BBMRI), Austria U.S.A. Bio-oriented Technology Research Advancement Albert Hung Foundation, Hong Kong, P.R. China Institution, National Agriculture and Food Research Algeria’s General Directorate for Scientific Research and Organization (NARO), Tsubuka, Japan Technological Development (DGRSDT), Algiers, Algeria Bioscience Group and Head, Radiation Biology & Health Alliance Pour la Recherche En Cancérologie (APREC), Sciences Division (BARC), Mumbai, India Paris, France Biozoom Services GmbH, Kassel, Germany Alma Toorock Memorial for Cancer Research, Brooklyn, Bone and Soft-Tissue Clinic, Peter McCallum Cancer NY, U.S.A. Institute, Melbourne, VIC, Australia American Association of Cancer Researchers, Philadelphia, Bonner Forschung (BONFOR ) Research Grant, University PA, U.S.A. Medical Center, University of Bonn, Bonn, Germany American Cancer Society, Atlanta, GA, U.S.A. Boston University School of Medicine (BUSM), Boston, American Chemical Society (ACS), Washington, DC, MA, U.S.A. U.S.A. Brain Tumour Foundation of Canada, London, ON, Canada American Heart Association, Dallas, TX, U.S.A. Breast Cancer Hope Foundation, London, U.K. American Journal Experts (AJE), Durham, NC, U.S.A. Breast Cancer Now, London, U.K. Asa Norte Regional Hospital (HRAN), Brasília, Brazil Breast Cancer Research Foundation, New York, NY, U.S.A. Asahi Kasei Pharma Corp., Tokyo, Japan Asan Institute for Life Sciences, Asan Medical Center, California State University Dominguez Hills, Carson, CA, Seoul, Republic of Korea U.S.A. Assistance Publique des Hôpitaux de Paris (APHP), Paris, Canadian Breast Cancer Foundation, Canada France Canadian Tumour Repository Network, Canada Austrian Science Fund (FWF), Vienna, Austria Cancer and Allergy Foundation, Gothenburg, Sweden Avtal om Läkarutbildning och Forskning (ALF), Lund Cancer Care West-Hardiman Scholarship, Galway, Ireland University and Region Skane, Lund, Sweden Cancer Registry, Hannover Medical School, Hannover, Germany Basic Science Research Program, National Research Cancer Research Foundation Norrland, Umeå, Sweden Foundation of Korea (NRF), Ministry of Education, Cancer Research Society, Ottawa, ON, Canada Science and Technology, Seoul, Republic of Korea Cancer Research Wales, Wales, U.K. Bavarian State Ministry of the Environment and Consumer Cancer Society, Stockholm, Sweden Protection, Munich, Germany Cancéropôle Grand Ouest, Lille, France Bayer HealthCare Pharmaceuticals, Montville, NJ, U.S.A. Capacity Development Award, Canadian Cancer Society, Becket-Fonden, Copenhagen, Denmark Canada Beijing Municipal Science & Technology Commission, Cardiff China Medical Research Collaborative, Cardiff Beijing, P.R. China University, Wales, U.K. Benson Idahosa University, Benin City, Nigeria Cardiff University’s China Medical Scholarship, Cardiff Beppu Medical Center, Beppu, Japan University, Wales, U.K. Berlin Institute of Health, Berlin, Germany Catholic Medical Center Research Foundation, Seoul, Bettina Bräu Foundation, Munich, Germany Republic of Korea ANTICANCER RESEARCH 37 : (2017)

Center for Advanced Molecular Medicine, Fukuoka Compagnia di San Paolo, Turin, Italy University, Fukuoka, Japan Comprehensive Cancer Center, Wake Forest University Center for Cellular and Molecular Medicine, Kyushu Baptist Medical Center, Winston-Salem, NC, U.S.A. University Hospital, Fukuoka, Japan Comprehensive Support Project for Cooperative Clinical Center for Drug Design, Academic Health Center, Research, Public Health Research Foundation, Tokyo, University of Minnesota, Minneapolis, MN, U.S.A. Japan Center for Neuroscience Research, Children's Research Conceptual Development of Research Organization, Institute, Children's National Medical Center, Faculty Hospital in Pilsen (FNPI), Ministry of Health, Washington, DC, U.S.A. Prague, Czech Republic Center of Innovation Program, Japan Science and Conseil Départemental de Haute Corse, Bastia, Corsica, Technology Agency (JST), Kawaguchi, Japan France Center of Life Sciences, Hiroshima University, Conselho Nacional de Desenvolvimento Cientifico e Higashihiroshima, Japan Tecnologico (CNPq), Brasilia, Brazil Centre National de la Recherche Scientifique (CNRS), Cooperation in Science and Technology (COST), EU RTD Paris, France Framework Program, Brussels, Belgium Chang Gung Memorial Hospital, Taipei, Taiwan, R.O.C. Cooperative Research Grant, Institute for Enzyme Charité Universitätsmedizin Berlin, Berlin, Germany Research, Joint Usage/Research Center, University of Charles R. Drew University of Medicine and Science, Tokushima, Tokushima, Japan Willowbrook, CA, U.S.A. Cooperative Research Program, Network Joint Research China Medical University Hospital, Taichung, Taiwan, R.O.C. Center for Materials and Devices, Osaka, Japan China Medical University, Taichung, Taiwan, R.O.C. Coordenação de Aperfeiçoamento de Pessoal de Nível China Natural Science Foundation, Guangdong, P.R. China Superior (CAPES), Brasilia, Brazil China Scholarship Council, Beijing, P.R. China Council for Science, Technology and Innovation (CSTI), ChromoTek, Martinsried, Germany Tokyo, Japan Chulalongkorn University, Bangkok, Thailand Council Of Scientific & Industrial Research (CSIR)- Chungnam National University, Daejeon, Republic of Central Food Technological Research Institute (CFTRI), Korea Mysuru, India Circulating Tumor Cells Therapeutic Apheresis Council of Scientific & Industrial Research (CSIR) (CTCTRAP), the Netherlands Scientific & Industrial Research (SRF), University City of Hope, National Medical Center, Duarte, CA, U.S.A. Grants Commission (UGC), New Delhi, India Clarient Inc., Aliso Viejo, CA, U.S.A. Croatian Science Foundation, Zagreb, Croatia Claudia von Schilling Foundation for Breast Cancer Cross-ministerial Strategic Innovation Promotion Program Research, Hannover, Germany (SIP), Japan Cleveland Clinic, Cleveland, OH, U.S.A. Clinical Research Institute, National Kyushu Cancer Danish Cancer Society, Copenhagen, Denmark Center, Fukuoka, Japan Danish Center for Interventional Research in Radiation Clinical Research Support (CRES) Center Kyushu, Oncology (CIRRO), The Lundbeck Foundation Centre Fukuoka City, Japan for Interventional Research in Radiation Oncology, Clinical Sciences Research and Development Program, Aarhus, Denmark Department of Veterans Affairs, Washington, DC, U.S.A. Danish Council for Strategic Research, Copenhagen, Clinical Trial and Research Center of Excellence, Ministry Denmark of Health and Welfare, Taipei, Taiwan, R.O.C. Danish Head and Neck Cancer Group (DAHANCA), Cluster of Excellence Engineering of Advanced Materials Aarhus, Denmark (EAM), Erlangen, Germany Dansk Kraeftforsknings Fund, Copenhagen, Denmark Collaborative Innovation Center of Chinese Oolong Tea Darren Manelski Foundation, U.S.A. Industry, College of Tea and Food Science, Wuyi Dartmouth Synergy Clinical and Translational Science University, Wuyishan, P.R. China Institute, National Center for Advancing Translational Commission on Cancer, American College of Surgeons, Sciences (NCATS), National Institutes of Health (NIH), Chicago, IL, U.S.A. Bethesda, MD, U.S.A. ANTICANCER RESEARCH 37 : (2017)

David Geffen School of Medicine at UCLA, Los Angeles, Department of Pathology, Radiumhospitalet, Oslo CA, U.S.A. University Hospital, Oslo, Norway Deanship of Scientific Research (DSR), King Abdulaziz Department of Radiation Oncology, Gunma University, University, Jeddah, Kingdom of Saudi Arabia Maebashi, Japan Dell’Angelo Hospital Mestre-Venice, Venice, Italy Department of Science and Technology, Guangxi Province, Department of Clinical Research Center, Wakayama P.R. China Medical University, Wakayama , Japan Department of Veterans Affairs, Washington, DC, U.S.A. Department of Comprehensive Clinical Oncology, Faculty Departments of Surgical Pathology, Library, Medical of Medical Sciences, Kyushu University, Fukuoka, Japan Media and Research Services, Minneapolis VA Medical Department of Environmental, Biological and Center, Minneapolis, MN, U.S.A. Pharmaceutical Sciences and Technologies, Second Departments of Urology, Radiology and Radiation University of Naples, Caserta, Italy Oncology, Osaka Medical College, Takatsuki, Japan Department of Gastroenterological Surgery and Urology, Dermal Toxicology and Effects Group, Centre for Osaka University, Osaka, Japan Radiation, Chemical and Environmental Hazards, Public Department of Gastroenterology and Hepatology, Osaka Health England, U.K. University, Osaka, Japan Des Moines University, Des Moines, IA, U.S.A. Department of Health, Biotechnology Research Program, Desna Robins Jones Charitable Trust, Bridgend, U.K. Commonwealth of Pennsylvania, U.S.A. Deutsche Forschungsgemeinschaft (DFG), Bonn, Germany Department of Histology and Embryology, Wroclaw Deutsche Krebshilfe, Bonn, Germany Medical University, Wroclaw, Poland DexTech Medical AB, Uppsala, Sweden Department of Integrative medicine, Osaka University, Diversity Grant, National Institute of Radiological Sciences Osaka, Japan (NIRS)-Chiba University, Japan Department of International Medical Communications, Division of Gastroenterology and Hepatology, University Tokyo Medical University, Tokyo, Japan of Wisconsin, Madison, WI, U.S.A. Department of Medical Sciences, The Graduate School, Dynamic Science S.L., Barelona, Spain Ajou University, Suwon¸ Republic of Korea Department of Medicine and Biosystemic Science, Edanz, Fukuoka, Japan Graduate School of Medical Sciences, Kyushu Editage, Tokyo, Japan University, Fukuoka City, Japan Eisai GmbH, Frankfurt, Germany Department of Medicine, University of Wisconsin, Eli Lilly and Company, Indianapolis, IN, U.S.A. Madison, WI, U.S.A. Else og Mogens Wedell-Wedellsborgs Fond, Skodsborg, Department of Molecular Pharmacology and Oncology, Denmark Gunma University Graduate School of Medicine, Gunma, Enrico and Enrica Sovena Foundation, Italy Japan European Institute of Oncology, Milan, Italy Department of Nuclear Medicine, Taichung Tzu Chi European Regional Development Fund (ERDF), Brussels, Hospital, Taichung, Taiwan, R.O.C. Belgium Department of Obstetrics and Gynecology, University of European Social Fund (ESF), European Commission, Tübingen, Tübingen, Germany Brussels, Belgium Department of Oncology, University Hospital of Ioannina, European Structural and Investment Funds , European Ioannina, Greece Commission, Brussels, Belgium Department of Ophthalmology, University Medical Center EuroTransBio (ETB), Seventh Framework Programme, Hamburg-Eppendorf (UKE), Hamburg, Germany European Commission, Brussels, Belgium Department of Oral Pathology, Institute of Pathology, Experimental Pathology, University of Wisconsin Carbone Universitätsklinik Hamburg-Eppendorf, Hamburg, Germany Cancer Center, Madison, WI, U.S.A. Department of Orthopaedics, St. Vincent’s Hospital Ez Communications, Matsumoto, Japan Melbourne, Fitzroy, VIC, Australia Department of Pathology and Laboratory Medicine F. Hoffmann-La Roche AG, Basel, Switzerland Service, Minneapolis VA Medical Center, Minneapolis, Fabrikant Einer Willumsens Mindelegat, Copenhagen, MN, U.S.A. Denmark ANTICANCER RESEARCH 37 : (2017)

Fabrikant Willumsens Mindelegat, Copenhagen, Fukuoka Higashi Medical Center, Koga, Japan Denmark Fund for Scientific Research – Flanders (FWO - Faculté des Sciences Pharmaceutiques et Biologiques, Vlaanderen), Brussels, Belgium Université Paris Descartes, Paris, France Fundação Araucária do Paraná, Curitiba , PR, Brazil Faculty Hospital in Pilsen (FNPl), Pilsen, Czech Republic Fundação para a Ciência e a Tecnologia (FCT), Ministério Faculty of Medicine in Pilsen, Charles University in da Ciência e Ensino Superior, Portugal Prague, Pilsen, Czech Republic Fundamental Research Grant, South University of Science Faculty of Medicine Publication Clinic, Khon Kaen and Technology of China, Shenzhen, P.R. China University, Khon Kaen, Thailand Funding for Excellent Departments, Qingdao University, Faculty of Pharmaceutical Sciences, Chulalongkorn Qingdao, P.R. China University, Bangkok, Thailand Fundo Estadual para a Infância e Adolescência (FIA/PR), Fellowships of Excellence for Postgraduate Studies in Curitiba, PR, Brazil Greece-Siemens Program, State Scholarships Foundation (IKY), Athens, Greece Galenus-med GmbH, Frankfurt am Main, Germany Finnish Anti-tuberculosis Association, Helsinki, Finland Galway University Foundation , Galway, Ireland Finnish Cancer Society, Helsinki, Finland Gänseblümchen-Voerde Foundation, Voerde, Germany Finnish Dental Society Apollonia, Helsinki, Finland Gazdaságfejlesztési és Innovációs Operatív Program Finnish Medical Foundation, Helsinki, Finland (GINOP), Hungary Finnish Medical Society Duodecim, Helsinki, Finland GE Healthcare, Chigaco, Il, U.S.A. Finnish Society For Oncology, Helsinki, Finland Genomics and Proteomics Core Laboratory, Department of Flint Animal Cancer Center, Colorado State University, Medical Research, Kaohsiung Chang Gung Memorial Fort Collins, CO, U.S.A. Hospital, Kaohsiung, Taiwan, R.O.C. Fondation des Hôpitaux Enfant-Jésus – St-Sacrement German Academic Exchange Program (DAAD), New York, (HEJ-SS), Ville de Québec, QC, Canada NY, U.S.A. Fondation du Cancer du Sein du Québec, Ville de Québec, German Federal Ministry of Education and Research QC, Canada (BMBF), Germany Fondation pour la Recherche Médicale (FRM), Paris, German Institute of Human Nutrition, Nuthetal, Germany France Gesellschaft für KinderKrebsForschung e.V., Geltendorf, Fondazione Comunità Bresciana Onlus, Brescia¸Italy Germany Fondazione Guido Berlucchi per la Ricerca sul Cancro Global Robotics Institute, Florida Hospital, Orlando, FL, Onlus, Borgonato, Italy U.S.A. Fonds de recherche du Québec - Santé (FRQS), Montréal, Golfer’s Against Cancer Grant, Kingwood, TX, U.S.A. QC, Canada Gout Research Foundation, Tokyo, Japan Förderung für Forschung und Lehre, LMU University, Grand Forks Human Nutrition Research Center, Grand Munich, Germany Forks, ND, U.S.A. Forschungsförderung Ruhr-Universität Bochum Grant-in-Aid for Clinical Cancer Research, Ministry of Medizinischen Fakultät (FoRUM) Grant, Ruhr-University Health, Labor and Welfare, Tokyo, Japan Bochum, Bochum , Germany Grant-in-Aid for Exploratory Research, Ministry of Foundation for Polish Science, Warsaw, Poland Education, Culture, Sports, Science and Technology Foundation for Promotion of Cancer Research, Tokyo, (MEXT), Tokyo, Japan Japan Grant-in-Aid for Graduate Students, Hyogo College of Foundation of Beijing Educational Committee, Beijing, Medicine, Nishinomiya, Japan P.R. China Grant-in-Aid for Scientific Research, Ministry of Health, Foundation of Skin Physiology, Donors' Association for the Labor and Welfare of Japan, Tokyo, Japan Promotion of Sciences and Humanities in Germany, Grants-in Aid for Cancer Research: Research on HTLV-1 Germany Associated Diseases, Saga Prefecture, Japan French Ministery of Health as part of Grants-in Aid for Cancer Research: Special Cancer Friedrich-Baur Foundation, Munich, Germany Research, Ministry of Education, Science, Sports and Frits, Georg og Marie Gluds Legat, Aarhus, Denmark Culture, Tokyo, Japan ANTICANCER RESEARCH 37 : (2017)

Grants-in-Aid for Scientific Research (KAKENHI), Japan Innovative Economy Operational Program, Provincial Society for the Promotion of Science, Tokyo, Japan Specialized Hospital, Research and Development Center, Gujarat Council on Science and Technology, Gujarat, India Wroclaw, Poland Gujarat State Biotechnology Mission, Gujarat, India Innovative Social Policies for Inclusive and Resilient Gunnar Nilssons Cancerstiftelse, Helsingborg, Sweden Labour Markets in Europe (INsPiRE), Seventh Framework Programme, European Commission, Hans-Sauer-Stiftung, Oberhaching, Germany Brussels, Belgium Harvard Medical School, Boston, MA, U.S.A. Inoue Enryou Memorial Foundation, Toyo University, Health and Welfare Data Science Center (HWDC), Taipei, Tokyo, Japan Taiwan, R.O.C. Institut Curie, Paris, France Health Labour Sciences Research Grant, Ministry of Health Institut National de la Santé et de la Recherche Médicale, Labour and Welfare, Tokyo, Japan France Health Research Board, Dublin, Ireland Institute of Biomathematics, Faculty of Medicine, Heavy Ion Medical Accelerator in Chiba (HIMAC), Chiba, Mannheim, Germany Japan Institute of Bioorganic Chemistry Core Facility (CKP Henry M. Jackson Foundation for the Advancement of IBCH), Moscow, Russian Federation Military Medicine, Bethesda, MD, U.S.A. Institute of Dentistry, University of Turku, Turku, Finland Heriot Watt University (HWU), Edinburgh, Scotland, Institute of Health Biosciences, University of Tokushima, U.K. Tokushima, Japan Higher Education Commission of Pakistan (FAM), Institute of Lighting Technics, Technical University Berlin, Islamabad, Pakistan Berlin, Germany Higher Education Research Promotion, Bangkok, Thailand Instituto de Medicina Molecular, Faculdade de Medicina de Hiroshima Red Cross Hospital & Atomic Bomb Survivors Lisboa, Lisbon, Portugal Hospital, Hiroshima, Japan Internal Grant Agency (IGA), Ministry of Health, Prague, Hoffmann-La Roche Pharmaceuticals, Basel, Switzerland Czech Republic Hokkaido University, Sapporo, Japan International Comparisons of Product Supply Chains in the Hospital Pharmacy, Fondazione IRCCS Policlinico San Agro-food Sectors (COMPETE), Seventh Framework Matteo, Pavia, Italy Programme, European Commission, Brussels, Belgium Hubei Key Laboratory of Stem Cell Research, Taihe IPSEN Pharma GmbH, Ettlingen, Germany Hospital, Hubei University of Medicine, Shiyan, P.R. Ireland Alumni Student Research Programme , Royal China College of Surgeons, Dublin, Ireland Hubei Science and Technology Foundation, Shiyan, P.R. Irish Cancer Society, Dublin, Ireland China Italian Association for Cancer Research (Associazione Hyogo Medical Center, Akashi, Japan Italiana per la Ricerca sul Cancro, AIRC), Italy Hyogo Prefecture Health Promotion Association, Ithoh-Chubei Foundation, Japan Nishinomiya, Japan James and Esther King Florida Biomedical Research Icahn School of Medicine at Mount Sinai, New York, NY, Program, Florida Department of Health, Tallahassee, FL, U.S.A. U.S.A. Ichiro Kanehara Foundation, Japan János Bolyai Research Scholarship, Hungarian Academy of Iizuka Hospital, Fukuoka, Japan Sciences, Budapest, Hungary Imperial Life Sciences (P) Limited, Gurugram, India Japan Agency for Medical Research and Development Incubating Program for Clinical Research and Innovation, (AMED), Tokyo, Japan Renji Hospital Affiliated to Shanghai Jiao Tong Japan Foundation for Applied Enzymology (JFAE), Osaka, University School of Medicine, Shanghai, P.R. China Japan Indian Council for Medical Research, New Delhi, India Japan Science and Technology Agency (JST), Kawaguchi, Innovative Economy Operational Program, National Japan Strategic Reference Framework Program, European Japan Society for the Promotion of Science (JSPS), Tokyo, Union, Brussels, Belgium Japan ANTICANCER RESEARCH 37 : (2017)

Jeju National University Hospital, Jeju, Republic of Korea Laboratory for Process Engineering, Environment, John P. Murtha Cancer Center, Johnstown, PA, U.S.A. Biotechnology and Energy (LEPABE), Faculty of Johns Hopkins University, Baltimore, MD, U.S.A. Engineering of Porto (FEUP), Porto, Portugal Jules Bordet Institute, Free University of Brussels, Lancaster – Coty International Inc., London, U.K. Brussels, Belgium Laval University Cancer Research Center, Laval, QC, Canada K2R2R Award, Intermountain Foundation, Primary Lega Italiana Per La Lotta Contro i Tumori (LILT), Naples, Children's Hospital, Salt Lake City, UT, U.S.A. Italy Kakihara Science and Technology Foundation, Fukuoka, Les Amis de Bordet, Brussels, Belgium Japan Life Sciences Research Network Wales, Wales, U.K. Kanagawa Health Foundation, Japan Lifelong Learning Programme (LLP) Erasmus Programme, Kanagawa Prefectural Hospitals Cancer Fund, Japan European Union Kanazawa Medical Research Foundation, Kanazawa, London Regional Cancer Program, London, U.K. Japan Louis Stokes Alliances for Minority Participation (LSAMP) Kaohsiung Medical University Hospital, Kaohsiung City, National Science Foundation Grant, Arlington, VA, Taiwan, R.O.C. U.S.A. Kaohsiung Veterans General Hospital, Kaohsiung City, Ludwig-Maximilians-University (LMU), Munich, Germany Taiwan, R.O.C. Karen A. Tolstrups Fund, Denmark M.D. Anderson Cancer Center, Houston, TX, U.S.A. Karl-Olga-Krankenhaus GmbH, Stuttgart, Germany MacArthur Foundation, Chicago, IL, U.S.A. Karolinska Institutet, Stockholm, Sweden Magnetic Resonance Imaging Center, Hamburg, Germany KfH Nephrological Center Moabit, Berlin, Germany Mama Mare Breast Cancer Foundation, Easton, PA, U.S.A. Khon Kaen University, Khon Kaen, Thailand Manchester Metropolitan University, Manchester, U.K. King Abdulaziz City for Science and Technology Marienhospital Stuttgart, Stuttgart, Germany (KACST), Riyadh, Saudi Arabia Masaryk Memorial Cancer Institute, Brno, Czech Republic King Gustav V Jubilee Fund, Stockholm, Sweden Max og Inger Wørzners Mindelegat, Denmark Klinikum Stuttgart, Stuttgart, Germany Media Service, Minneapolis Veterans Affairs Medical Kochi Medical Center, Kochi, India Center, University of Minnesota, Minneapolis, MN, Kochi University Hospital, Kochi, India U.S.A. Korea Health Industry Development Institute (KHIDI), Medical Prognosis Institute, Hørsholm, Denmark Ministry of Health & Welfare, Seoul, Medical Research Core Facilities Center, Office of Republic of Korea Research & Development, China medical University, Korea Health Technology R&D Project, Ministry of Health Taichung, Taiwan, R.O.C. & Welfare, Seoul, Republic of Korea Medical School, University of Ioannina, Ioannina, Greece Korea Institute of Radiological and Medical Sciences Medical University of Gdańsk, Gdańsk, Poland (KIRAMS), Ministry of Science, ICT and Future Medical-Engineering Joint Fund, Shanghai Jiao Tong Planning, Gwacheon, Republic of Korea University, Minhang Qu, P.R. China Korean Health Technology R&D Project, Ministry of Medi-Kelsey Ltd, Ashbourne, U.K. Health & Welfare, Seoul, Republic of Korea Meikai University School of Dentistry, Urayasu, Japan Kuopio University Hospital, Kuopio, Finland Memorial Sloan Kettering Cancer Center, Department of KUREHA Co. Ltd., Tokyo, Japan Pathology, New York, NY, U.S.A. Kyoto University, Kyoto, Japan Ministry of Agriculture, Forestry and Fisheries, Tokyo, Kyowa Hakko Kirin Co. Ltd., Tokyo, Japan Japan Kyushu Central Hospital, Fukuoka, Japan Ministry of Economics and Science of the Saarland, Kyushu University Hospital, Fukuoka, Japan Germany Kyushu University, Fukuoka, Japan Ministry of Education Youth and Sports, Prague, Czech Republic Laboratory Animal Facilities, Jikei University School of Ministry of Education, Culture, Sports, Science and Medicine, Tokyo, Japan Technology (MEXT), Tokyo, Japan ANTICANCER RESEARCH 37 : (2017)

Ministry of Education, Science and Technology, Seoul, National Institute on Aging, Bethesda, MD, U.S.A. Republic of Korea National Institutes of Health, Department of Health and Ministry of Health & Welfare, Sejong City, Republic of Human Services, Bethesda, MD, U.S.A. Korea National Kyushu Cancer Center, Japan Ministry of Health and Welfare, Executive Yuan, Taipei, National Natural Science Foundation of China, Guangdong, Taiwan, R.O.C. P.R. China Ministry of Health, Labor and Welfare, Tokyo, Japan National Natural Science Foundation of Zhejiang Province, Ministry of Health, Prague, Czech Republic Zhejiang, P.R. China Ministry of Science and Higher Education, Warsaw, Poland National Plan for Science, Technology and Innovation Ministry of Science and Technology, Taipei, Taiwan, (MAARIFAH), Riyadh, Kingdom of Saudi Arabia R.O.C. National R&D Program, Korea Institute of Radiological Ministry of Science and Technology, Taipei, Taiwan, R.O.C. a n d M e d i c a l S c i e n c e s , M inistry of Science, ICT & Ministry of Science, Education and Sports (MZOS), Future Planning (MSIP), Gwacheon, Republic of Korea Zagreb, Republic of Croatia National Research Council, Khartoum, Sudan Ministry of Science, ICT & Future Planning (MSIP), National Research Foundation of Korea (NRF), Ministry of Gwacheon, Republic of Korea Education, Science and Technology, Seoul, Republic of Molecular-Genetics Laboratory, Department of Hematology Korea and Oncology, Faculty Hospital Pilsen, Pilsen, Czech National Research Network Wales, Wales, U.K. Republic National Research Program in Biomedicine, Latvia Mrs. Berta Kamprad Foundation, Sweden National Science Centre (NCN), Krakow, Poland Münchener Medizinische Wochenschrift (MMW), Germany National Science Council of Taiwan, Taipei, Taiwan, MVZ Labor Limbach Berlin GbR, Berlin, Germany R.O.C. National Science Foundation (NSF), Arlington, VA, U.S.A. Nagasaki University Graduate School of Biomedical National Science Fund of Bulgaria, Sofia, Bulgaria Science, Nagasaki, Japan National Sustainability Program I (NPU I), Ministry of Nagoya City University Graduate School of Medical Education Youth and Sports, Prague, Czech Republic Sciences, Nagoya, Japan Natural Science Foundation of Shandong Province, Nakatomi Foundation, Tokyo, Japan Shandong, P.R. China Nakatsu Municipal Hospital, Nakatsu, Japan Natural Science Foundation, Jiangsu Science and Nambour Skin Cancer Study, Nambour, QLD, Australia Technology Department, Jiangsu, P.R. China Nanotechnology Innovation Center Kansas State (NICKS), Neurofibromatosis Outpatient Center, Department of Manhattan, KS, U.S.A. Neurology, Universitätsklinikum Hamburg-Eppendorf National Agency for Scientific Research (NASR), Tripoli, (UKE), Hamburg, Germany Libya NHO Kochi Hospital, Kochi, Japan National Cancer Center Research and Development Fund, NHS Endowment, National Health Service, London, U.K. Japan NIH Intramural Research Program, Bethesda, MD, National Cancer Database (NCDB), Chicago, IL, U.S.A. U.S.A. National Cancer Institute, National Institutes of Health, Nikon Instruments, Minneapolis, MN, U.S.A. Bethesda, MD, U.S.A. Nine Fields of Occupational Injuries and Illnesses , National Center for Research Resources, NIH, Bethesda, Ministry of Health, Labour, and Welfare, Tokyo, Japan MD, U.S.A. Nippon Suisan Kaisha, Ltd., Tokyo, Japan National Institute for General Medical Sciences (NIGMS), Northumbria University (NNU), Newcastle upon Tyne, Bethesda, MD, U.S.A. U.K. National Institute of Allergy and Infectious Diseases Norwegian Institute of Public Health (NIPH), Oslo, (NIAID), NIH, Bethesda, MD, U.S.A. Norway National Institute of Minority Health and Health Norwegian Radium Hospital Research Foundation, Oslo, Disparities (NIMHD), NIH, Bethesda, MD, U.S.A. Norway National Institute of Radiological Sciences (NIRS), Chiba, Novartis Pharmaceuticals Corporation, New York, NY, Japan U.S.A. ANTICANCER RESEARCH 37 : (2017)

Odense University Hospital, Odense, Denmark Radiation Biobank, Korea Institute of Radiological and Office of the Higher Education Commission, National Medical Sciences (KIRAMS), Seoul, Republic of Korea Research University Project of Thailand, Thailand Radiosensitivity of Individuals and Susceptibility to Cancer OitA Cancer Research Foundation, Oita, Japan induced by Ionizing Radiations (RiscRad), Euratom - Oita Medical Center, Oita, Japan European Commission Oita Prefectural Hospital, Oita, Japan Radiumstationens Forskningsfond, Aarhus, Denmark Oita Red Cross Hospital, Oita, Japan Ratchadaphiseksomphot Endowment Fund, Chulalongkorn Oncological Clinical Research Program, Minister of Health University , Thailand and Solidarity, Paris, France Research and Development Center, Provincial Specialized Onyx Pharmaceuticals, Inc., Whippany, NJ, U.S.A. Hospital, Wroclaw, Poland Országos Tudományos Kutatási Alapprogramok (OTKA), Research Centers in Minority Institutions (RCMI) Center Budapest, Hungary for Environmental Health, Jackson State University Osaka City University Graduate School of Medicine, (JSU), Jackson, MS, U.S.A. Osaka, Japan Research Council of Lithuania, Vilnius, Lithuania Oslo University Hospital, Oslo, Norway Research Council of Norway, Lysaker, Norway Research Potential of Convergence Regions (REGPOT), Palacký University, Olomouc, Czech Republic Seventh Framework Programme, European Commission, Pathology Department, Santo António Hospital, Porto, Brussels, Belgium Portugal Research Service, Minneapolis Veterans Affairs Medical Pathology Service, Saint-Sacrement Hospital, Quebec City, Center, Minneapolis, MN, U.S.A. QC, Canada Research Support Center, Division of Clinical Science, Pathology Translational Research Laboratory, NCI- Dokkyo Medical University, Tochigi, Japan designated Norris Cotton Cancer Center, Lebanon, NH, Réseau de Recherche sur le Cancer, Fonds de la Recherche U.S.A. en Santé du Québec (FRQS), Montréal, QC, Canada Pathology Translational Research Laboratory, Norris Respiratory Clinic, Turku University Hospital, Turku, Cotton Cancer Center, Lebanon, NH, U.S.A. Finland Plains Area, Agricultural Research Service(ARS), U.S. rgb Onkologisches Management GmbH, Sarstedt, Germany Department of Agriculture (USDA), Washington, DC, RIKEN Advanced Institute for Computational Science, U.S.A. Wako, Japan Positive Bioscience, Mumbai, India Robert-Bosch-Hospital, Stuttgart, Germany Practical Research for Innovative Cancer Control, Japan Roche Diagnostics GmbH, Penzberg, Germany Agency For Medical Research and Development Roche Pharma AG, Grenzach-Wyhlen, Germany (AMED), Tokyo, Japan Roche Products Pvt. Ltd., Mumbai, India Preclinical Research Platform (PFEP), Villejuif, France Rouen University Hospital, Rouen, France Premas Life Science, Delhi, India Russian Science Foundation (RSF), Moscow, Russian Princess Margaret Cancer Foundation, Toronto, ON, Canada Federation Priority Research Fund, Osaka City University, Osaka, Japan Sabinsa Corporation – NJ, East Windsor, NJ, U.S.A. Program to Support Young Scientists, Bulgarian Academy Saga University, Saga, Japan of Science, Sofia, Bulgaria Saiseikai Fukuoka General Hospital, Fukuoka, Japan Programa Operacional Competitividade e Saiseikai Karatsu Hospital, Karatsu, Japan Internacionalização (POCI), Lisbon, Portugal Saiseikai Yahata Hospital, Yahata, Japan Project “Terapie Innovative per il Glioblastoma”, IRCCS Sapienza Ateneo, Rome, Italy AOU San Martino - IST, Genoa, Italy Sbarro Health Research Organization (SHRO), Pennsylvania Publication Clinic, Faculty of Pharmacy, Khon Kaen Department of Health, Philadelphia, PA, U.S.A. University, Khon Kaen, Thailand SBI Pharmaceuticals Co., LTD., Tokyo, Japan Scare Crow Inc., Tokyo, Japan Quadro de Referência Estratégica Nacional (QREN), School of Medicine and Public Health, University of Portugal Wisconsin, Madison, WI, U.S.A. ANTICANCER RESEARCH 37 : (2017)

School of Medicine, Ajou University, Suwon, Republic of Stanley Tessis Fund, Toronto, ON, Canada Korea Startup Funds, Ministry of Education (MOE), Beijing, P.R. Schulich School of Medicine and Dentistry, London, ON, China Canada Steel Memorial Yahata Hospital, Kitakyushu, Japan Science and Technology Unit, King Abdulaziz University, Stockholm Cancer Society, Stockholm, Sweden Jeddah, Kingdom of Saudi Arabia Stockholm City Council, Stockholm, Sweden Scientific Grant Agency, Ministry of Education, Science, Study of the Health Effects of Radiation, Ministry of the Research and Sport, Bratislava, Slovak Republic Environment, Tokyo, Japan Screening Core Facility, National Centre for Biomedical Supercomputer System, Human Genome Center, Institute Engineering Science (NCBES), Galway, Ireland of Medical Science, University of Tokyo, Tokyo, Japan Secretaria da Ciência, Tecnologia e Ensino Superior Supported Programs for the Strategic Research Foundations (SETI), Curitiba , PR, Brazil at Private Universities, MEXT, Japan Secretaria da Família e Desenvolvimento Social (SEDS), Swedish Breast Cancer Association Curitiba, PR, Brazil (Bröstcancerföreningarnas Riksorganisation, BRO), Seoul National University Hospital (SNUH) Research Stockholm, Sweden Fund, Seoul, Republic of Korea Swedish Cancer Foundation, Stockholm, Sweden Shandong Province Young and Middle-aged Scientists Swedish Cancer Society, Stockholm, Sweden Research Award of China, P.R. China Szeged Foundation for Cancer Research (Szegedi Shanghai Fund for Young Physician Development, Rákkutatásért Alapítvány), Szeged, Hungary Shanghai, P.R. China Shanghai Pujiang Program, Shanghai, P.R. China Tagawa Municipal Hospital, Tagawa, Japan Shared Resource Support Grant, University of Colorado Taichung Armed Forces General Hospital, Taichung, Cancer Center, Denver, CO, U.S.A. Taiwan, R.O.C. Shenzhen Municipal Research Funds, Shenzhen, Hong Taichung Tzu Chi Hospital, Taichung, Taiwan, R.O.C. Kong, P.R. China Taiho Pharmaceutical Co. Ltd., Tokyo, Japan Shin-Nakama Hospital, Nakama, Japan Taiwan Academia Sinica Thematic Project, Taiwamn, R.O.C. Shizuoka Cancer Center Hospital, Shizuoka, Japan Takeda Chemical Inductries Show Chwan Memorial Hospital, Changhua, Taiwan, Takeda Science Foundation, Japan R.O.C. Taoyuan General Hospital, Ministry of Health and Welfare, Sint Antonius Hospital, Nieuwegein, the Netherlands Taoyuan City, Taiwan R.O.C. Slovak Research and Development Agency (SRDA), Társadalmi Megújulás Operatív Program (TÁMOP), Bratislava, Slovak Republic Hungary Smoking Research Foundation (SRF), Tokyo, Japan Thailand Research Fund, Bangkok, Thailand Social Insurance Nakabaru Hospital, Kasuya, Japan Thelma Mäkikyrö Foundation, Sweden Sonja Wasowicz Stiftung zur Förderung der Medizinischen Thuréus foundation, Uppsala, Sweden Forschung, Essen, Germany Tissue Bank, China Medical University, Taichung, Taiwan Soonchunhyang University Research Fund, Asan, Republic R.O.C. of Korea Translational Research Informatics (TRI) Center, Kobe, South-Eastern Norway Regional Health Authority, Hamar, Japan Norway TRF Senior Research Grant, Thailand Research Fund, Specialization Project Research Grant, Pusan National Bangkok, Thailand University, Busan, Republic of Korea TriStar Technology Group, Rockville, MD, U.S.A. Specific Health Problem in Greater Mekong Sub-region Tsukuba University, Ibaraki, Japan (SHeP-GMS), Health Cluster, National Research Turku University, Turku, Finland University Project of Thailand, Thailand's Office of the Higher Education Commission (OHEC), Bangkok, Uehara Memorial Foundation, Tokyo, Japan Thailand Umea University, Umea, Sweden Spogaards Family Fund, Denmark Undergraduate Research Opportunities Program (UROP), Stanford University, Stanford, CA, U.S.A. Boston University, Boston, MA, U.S.A. ANTICANCER RESEARCH 37 : (2017)

Unit of Molecular Therapies, Department of Experimental Vanderbilt University School of Medicine, Nashville, TN, Oncology and Molecular Medicine, Fondazione IRCCS U.S.A. Istituto Nazionale dei Tumori, Milan, Italy Vasterbotten County Council (ALF), Umea, Sweden Unité de Nutition Humaine UMR 1019 INRA-UdA-Equipe Victor Babes University of Medicine and Pharmacy, ECREIN, St Genès Champanelle, France Timisoara, Romania United States Department of Defense, The Pentagon, Arlington, VA, U.S.A. Wake Forest University, Winston-Salem, NC, U.S.A. University of Aberdeen, Aberdeen, Scotland, U.K. Walter Reed National Military Medical Center, Bethesda, University of Aveiro, Aveiro, Portugal MD, U.S.A. University of Brescia, Brescia, Italy Wellcome Trust, London, U.K. University of Helsinki, Helsinki, Finland West Virginia IDeA Network of Biomedical Research University of Maryland., College Park, MD, U.S.A. Excellence, West Virginia, U.S.A. University of Michigan, Ann Arbor, MI, U.S.A. World Cancer Research Fund International, London, U.K. University of Minnesota, Minneapolis, MN, U.S.A. Wroclaw Medical University, Wroclaw, Poland University of Pécs, Pécs, Hungary Wrovasc – Integrated Cardiovascular Centre, Wroclaw, University of Salford, Salford, U.K. Poland University of South Florida (USF) Research Foundation, Tampa, FL, U.S.A. Yantai Science and Technology Program, Yantai University, University of Southern Denmark, Odense, Denmark Yantai, P.R. China University of Tübingen, Tübingen, Germany Yantai Yuhuangding Hospital Initiative Foundation for University of Wisconsin Carbone Cancer Center, Madison, Young, Yantai University, Yantai, P.R. China WI, U.S.A. Yen Tjing Ling Medical Foundation, Taiwan, R.O.C. University of Wisconsin, Madison, WI, U.S.A. UV-Technik, Hanau, Germany ANTICANCER RESEARCH 37 : (2017)

Instructions for Authors 2017 General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes. The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. Αll authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to peer-review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to AR are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal’s secretary, the reviewers and the printers.The Editors reserve the right to improve manuscripts on grammar and style. The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double – spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding 4 printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author’s opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges..

Tables. All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

References. Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of “Index Medicus” and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. Anticancer Res 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: Receptors for Reproductive Hormones (O’ Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973. ANTICANCER RESEARCH 37 : (2017)

Nomenclature and Abbreviations. Nomenclature should follow that given in “Chemical Abstracts”, “Index Medicus”, “Merck Index”, “IUPAC -IUB”, “Bergey’s Manual of Determinative Bacteriology”, The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (http://www.gene.ucl.ac.uk/). Approved mouse nomenclature may be obtained from http://www.informatics.jax.org/. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text. For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475. For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: http://www.iiar-submissions.com/login.html In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: [email protected]

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online subscription to Anticancer Research for the current year and all previous digital content since 2004. Requests should be addressed to the Editorial Office. Galley proofs should be returned corrected to the Editorial Office by email within two days.

Specific information and additional instructions for Authors 1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress. 2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees. 3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission. 4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers. ANTICANCER RESEARCH 37 : (2017)

5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author’s writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage. 6. Authors should pay attention to the following points when writing an article for AR: • The Instructions to Authors must be followed in every detail. • The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists. • The presentation of results should be simple and straightforward in style. Results and discussion should not he combined into one section, unless the paper is short. • Results given in figures should not be repeated in tables. • Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering. • Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification. • Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided. • Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided. • Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by… authors, year). • The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission. • By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers. 7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required. 8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee). 9. Articles submitted to AR may be rejected without review if: • they do not fall within the journal's policy. • they do not follow the instructions for authors. • language is unclear. • results are not sufficient to support a final conclusion. • results are not objectively based on valid experiments. • they repeat results already published by the same or other authors before the submission to AR. • plagiarism is detected by plagiarism screening services. (Rejection rate (2016): 66%). 10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal. 11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to [email protected] 12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor. 13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service. (This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

Copyright© 2017 - International Institute of Anticancer Research (G.J. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher. Reviews